A Study Evaluating TRIV-573 in Atopic Dermatitis

A Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Multiple Subcutaneous Doses of TRIV-573 in Participants With Moderate to Severe Atopic Dermatitis

The goal of this interventional study is to learn if TRIV-573 works to treat moderate to severe atopic dermatitis in adults. It will also evaluate the safety of TRIV-573.

Participants will receive 5 doses of the study intervention that they are randomized to (TRIV-573 or placebo).

The study duration for individual participants is up to 40 weeks, including a Screening period of up to 30 days.

Inclusion Criteria:

• Has Atopic Dermatitis.
• Has moderate to severe, active and symptomatic atopic dermatitis.

Exclusion Criteria:

• Severe or uncontrolled medical conditions.
• Use of prohibited medications within stated washout periods.